Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Josephine V Lightowler a Department of Respiratory Medicine, St
James's University Hospital, Leeds LS9 7TF, b Academic Respiratory
Medicine, St Bartholomew's School and the Royal London School of
Medicine and Dentistry, London EC1A 7BE, c Department
of Physiological Medicine, St George's Hospital Medical School,
University of London, London SW17 0RE
Correspondence to: Felix S F Ram fram{at}sghms.ac.uk
Objectives:
To determine the effectiveness of
non-invasive positive pressure ventilation (NPPV) in the management of
respiratory failure secondary to acute exacerbation of chronic
obstructive pulmonary disease.
What is already known on this topic
A previous meta-analysis showed NPPV to be an effective intervention,
including for acute exacerbations of COPD, but some studies in this
meta-analysis contained mixed groups of patients and were not of good
quality What this study adds
NPPV should be considered early in the course of respiratory failure
and before severe acidosis ensues, to avoid the need for endotracheal
intubation and reduce mortality in patients with COPD
Design:
Systematic review of randomised controlled trials that compared NPPV and usual medical care with usual medical care alone in patients admitted to hospital with respiratory failure resulting from an exacerbation of chronic obstructive pulmonary disease
and with PaCO2 >6 kPa.
Results:
The eight studies included in the review
showed that, compared with usual care alone, NPPV as an adjunct to
usual care was associated with a lower mortality (relative risk 0.41 (95% confidence interval 0.26 to 0.64)), a lower need for intubation (relative risk 0.42 (0.31 to 0.59)), lower likelihood of treatment failure (relative risk 0.51 (0.38 to 0.67)), and greater improvements at 1 hour in pH (weighted mean difference 0.03 (0.02 to 0.04)), PaCO2 (weighted mean difference
0.40 kPa (
0.78 to
0.03)), and respiratory rate (weighted mean difference
3.08
breaths per minute (
4.26 to
1.89)). NPPV resulted in fewer
complications associated with treatment (relative risk 0.32 (0.18 to
0.56)) and shorter duration of stay in hospital (weighted mean
difference
3.24 days (
4.42 to
2.06)).
Conclusions:
NPPV should be the first line
intervention in addition to usual medical care to manage respiratory
failure secondary to an acute exacerbation of chronic obstructive
pulmonary disease in all suitable patients. NPPV should be tried early
in the course of respiratory failure and before severe acidosis, to
reduce mortality, avoid endotracheal intubation, and decrease treatment failure.
Prospective studies, especially the larger studies, have shown that
non-invasive positive pressure ventilation (NPPV) reduces the need for
intubation, improves survival, and reduces complications in patients
with respiratory failure resulting from exacerbation of chronic
obstructive pulmonary disease (COPD)
Evidence from good quality, randomised controlled trials shows that
NPPV is an effective treatment for acute exacerbations of
COPD
Read all Rapid Responses